The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy
<i>Background and Objectives:</i> Prediction of response to therapy remains a continuing challenge in treating breast cancer, especially for identifying molecular tissue markers that best characterize resistant tumours. Microribonucleic acids (miRNA), known as master modulators of tumour...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/10/1494 |
| _version_ | 1797471579569913856 |
|---|---|
| author | Lorena Alexandra Lisencu Andrei Roman Simona Visan Eduard-Alexandru Bonci Andrei Pașca Emilia Grigorescu Elena Mustea Andrei Cismaru Alexandru Irimie Cosmin Lisencu Loredana Balacescu Ovidiu Balacescu Oana Tudoran |
| author_facet | Lorena Alexandra Lisencu Andrei Roman Simona Visan Eduard-Alexandru Bonci Andrei Pașca Emilia Grigorescu Elena Mustea Andrei Cismaru Alexandru Irimie Cosmin Lisencu Loredana Balacescu Ovidiu Balacescu Oana Tudoran |
| author_sort | Lorena Alexandra Lisencu |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> Prediction of response to therapy remains a continuing challenge in treating breast cancer, especially for identifying molecular tissue markers that best characterize resistant tumours. Microribonucleic acids (miRNA), known as master modulators of tumour phenotype, could be helpful candidates for predicting drug resistance. We aimed to assess the association of miR-375-3p, miR-210-3p and let-7e-5p in breast cancer tissues with pathological response to neoadjuvant therapy (NAT) and clinicopathological data. <i>Material and methods</i>: Sixty female patients diagnosed with invasive breast cancer at The Oncology Institute “Ion Chiricuță”, Cluj-Napoca, Romania (IOCN) were included in this study. Before patients received any treatment, fresh breast tissue biopsies were collected through core biopsy under echographic guidance and processed for total RNA extraction and miRNA quantification. The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) database was used as an independent external validation cohort. <i>Results:</i> miR-375-3p expression was associated with more differentiated tumours, hormone receptor presence and lymphatic invasion. According to the Miller–Payne system, a higher miR-375-3p expression was calculated for patients that presented with intermediate versus (vs.) no pathological response. Higher miR-210-3p expression was associated with an improved response to NAT in both Miller–Payne and RCB evaluation systems. Several druggable mRNA targets were correlated with miR-375-3p and miR-210-3p expression, with upstream analysis using the IPA knowledge base revealing a list of possible chemical and biological targeting drugs. Regarding let-7e-5p, no significant association was noticed with any of the analysed clinicopathological data. <i>Conclusions:</i> Our results suggest that tumours with higher levels of miR-375-3p are more sensitive to neoadjuvant therapy compared to resistant tumours and that higher miR-210-3p expression in responsive tumours could indicate an excellent pathological response. |
| first_indexed | 2024-03-09T19:50:08Z |
| format | Article |
| id | doaj.art-68e06fc3970a4f97a98a873b9212518d |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T19:50:08Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-68e06fc3970a4f97a98a873b9212518d2023-11-24T01:12:13ZengMDPI AGMedicina1010-660X1648-91442022-10-015810149410.3390/medicina58101494The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant TherapyLorena Alexandra Lisencu0Andrei Roman1Simona Visan2Eduard-Alexandru Bonci3Andrei Pașca4Emilia Grigorescu5Elena Mustea6Andrei Cismaru7Alexandru Irimie8Cosmin Lisencu9Loredana Balacescu10Ovidiu Balacescu11Oana Tudoran12Department of Oncological Surgery and Gynecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Radiology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, RomaniaDepartment of Genetics, Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, RomaniaDepartment of Oncological Surgery and Gynecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Oncological Surgery and Gynecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Pathological Anatomy, County Emergency Hospital, 400347 Cluj-Napoca, RomaniaDepartment of Pathological Anatomy, County Emergency Hospital, 400347 Cluj-Napoca, RomaniaResearch Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400037 Cluj-Napoca, RomaniaDepartment of Oncological Surgery and Gynecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Oncological Surgery and Gynecological Oncology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Genetics, Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, RomaniaDepartment of Genetics, Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, RomaniaDepartment of Genetics, Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuță”, 400015 Cluj-Napoca, Romania<i>Background and Objectives:</i> Prediction of response to therapy remains a continuing challenge in treating breast cancer, especially for identifying molecular tissue markers that best characterize resistant tumours. Microribonucleic acids (miRNA), known as master modulators of tumour phenotype, could be helpful candidates for predicting drug resistance. We aimed to assess the association of miR-375-3p, miR-210-3p and let-7e-5p in breast cancer tissues with pathological response to neoadjuvant therapy (NAT) and clinicopathological data. <i>Material and methods</i>: Sixty female patients diagnosed with invasive breast cancer at The Oncology Institute “Ion Chiricuță”, Cluj-Napoca, Romania (IOCN) were included in this study. Before patients received any treatment, fresh breast tissue biopsies were collected through core biopsy under echographic guidance and processed for total RNA extraction and miRNA quantification. The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) database was used as an independent external validation cohort. <i>Results:</i> miR-375-3p expression was associated with more differentiated tumours, hormone receptor presence and lymphatic invasion. According to the Miller–Payne system, a higher miR-375-3p expression was calculated for patients that presented with intermediate versus (vs.) no pathological response. Higher miR-210-3p expression was associated with an improved response to NAT in both Miller–Payne and RCB evaluation systems. Several druggable mRNA targets were correlated with miR-375-3p and miR-210-3p expression, with upstream analysis using the IPA knowledge base revealing a list of possible chemical and biological targeting drugs. Regarding let-7e-5p, no significant association was noticed with any of the analysed clinicopathological data. <i>Conclusions:</i> Our results suggest that tumours with higher levels of miR-375-3p are more sensitive to neoadjuvant therapy compared to resistant tumours and that higher miR-210-3p expression in responsive tumours could indicate an excellent pathological response.https://www.mdpi.com/1648-9144/58/10/1494breast cancerneoadjuvant therapypathological complete responsemiR-375-3plet-7e-5pMiR-210-3p |
| spellingShingle | Lorena Alexandra Lisencu Andrei Roman Simona Visan Eduard-Alexandru Bonci Andrei Pașca Emilia Grigorescu Elena Mustea Andrei Cismaru Alexandru Irimie Cosmin Lisencu Loredana Balacescu Ovidiu Balacescu Oana Tudoran The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy Medicina breast cancer neoadjuvant therapy pathological complete response miR-375-3p let-7e-5p MiR-210-3p |
| title | The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy |
| title_full | The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy |
| title_fullStr | The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy |
| title_full_unstemmed | The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy |
| title_short | The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy |
| title_sort | role of mir 375 3p mir 210 3p and let 7e 5p in the pathological response of breast cancer patients to neoadjuvant therapy |
| topic | breast cancer neoadjuvant therapy pathological complete response miR-375-3p let-7e-5p MiR-210-3p |
| url | https://www.mdpi.com/1648-9144/58/10/1494 |
| work_keys_str_mv | AT lorenaalexandralisencu theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreiroman theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT simonavisan theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT eduardalexandrubonci theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreipasca theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT emiliagrigorescu theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT elenamustea theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreicismaru theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT alexandruirimie theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT cosminlisencu theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT loredanabalacescu theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT ovidiubalacescu theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT oanatudoran theroleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT lorenaalexandralisencu roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreiroman roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT simonavisan roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT eduardalexandrubonci roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreipasca roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT emiliagrigorescu roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT elenamustea roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT andreicismaru roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT alexandruirimie roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT cosminlisencu roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT loredanabalacescu roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT ovidiubalacescu roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy AT oanatudoran roleofmir3753pmir2103pandlet7e5pinthepathologicalresponseofbreastcancerpatientstoneoadjuvanttherapy |